CLINICAL & PIPELINE·Phase 3 Completion
Kelun-Biotech's Sac-TMT Phase 3 Success in China Signals Major Shift for PD-L1-Low NSCLC Treatment
Kelun-Biotech, partnered with Merck, announced positive Phase 3 results for sac-TMT in China for PD-L1-low non-squamous NSCLC. This antibody-drug conjugate demonstrated superior progression-free survival against chemotherapy, marking a critical advance for a challenging patient population. This validates Merck's significant ADC investment and signals a potential shift in front-line lung cancer treatment standards, impacting procurement and supply chain strategies globally.
90-Day Activity